AACE Patient Guide to Growth Hormone Deficiency

Understanding Growth Hormone Deficiency in Adults

Growth hormone deficiency (GHD) is one of those conditions that gets overshadowed by its more famous hormonal cousins like thyroid disease and low testosterone. Most people hear "growth hormone" and think about kids who need it to reach normal height. But adult-onset GHD is a real clinical entity that affects quality of life in ways that are often misdiagnosed or dismissed entirely. The American Association of Clinical Endocrinology (AACE) put this guide together to bridge the knowledge gap between patients and practitioners, and it covers ground that a lot of people in the optimization space should understand.

Adult GHD can arise from several causes. The most common is damage to the pituitary gland, whether from a tumor, surgery to remove a tumor, radiation therapy to the head or neck, or traumatic brain injury. Less commonly, it can result from genetic conditions or develop without a clear identifiable cause. The pituitary gland is surprisingly vulnerable to injury, and even mild traumatic brain injuries like concussions have been shown in some studies to impair pituitary function, sometimes years after the initial event.

What makes adult GHD tricky to diagnose is that its symptoms overlap with so many other conditions. Fatigue, increased body fat (particularly around the midsection), decreased muscle mass, poor exercise tolerance, low mood, disrupted sleep, and reduced bone density are all classic presentations. But these same symptoms could point to hypothyroidism, depression, low testosterone, metabolic syndrome, or simply the effects of aging and a sedentary lifestyle. Without specific testing, GHD is easy to miss.

How Growth Hormone Deficiency Gets Diagnosed

Diagnosing GHD in adults is not as straightforward as checking a single blood test. IGF-1 levels can provide a clue, since they tend to be low in GH-deficient adults, but a normal IGF-1 does not rule out GHD. The gold standard is a stimulation test, where the patient is given a substance that should trigger GH release (insulin, glucagon, or macimorelin), and blood is drawn at intervals to measure the response. If GH fails to rise above a certain threshold, the diagnosis is confirmed.

The insulin tolerance test (ITT) is considered the most reliable but also the most unpleasant. It involves inducing mild hypoglycemia, which stresses the body into releasing GH. For obvious reasons, this test has to be done under medical supervision and is contraindicated in people with seizure disorders or significant cardiovascular disease. The glucagon stimulation test and the macimorelin test are alternatives that are better tolerated, with macimorelin being the newest option and gaining popularity because it is an oral medication that does not require injections or induced hypoglycemia.

AACE guidelines recommend testing anyone with a known pituitary or hypothalamic disorder, history of head trauma, history of cranial radiation, or clinical features strongly suggestive of GHD. They specifically note that age-related decline in GH alone is not the same as clinical GHD and should not be treated as such without proper diagnostic workup.

The Difference Between GHD and Age-Related GH Decline

This distinction is worth emphasizing because it sits at the heart of one of the biggest debates in hormone optimization. Every adult experiences a gradual decline in GH output starting around age 25-30. By age 60, most people are producing significantly less GH than they did in their twenties. This is sometimes called somatopause, and it contributes to age-related changes in body composition, energy, and recovery.

But somatopause is not the same as growth hormone deficiency. GHD is a pathological condition where GH production has dropped below the level needed for normal physiological function. The decline of somatopause, while real, typically does not cross that clinical threshold. This matters because treatment guidelines, insurance coverage, and risk-benefit calculations are different for someone with true GHD versus someone with normal age-related decline who wants to feel like they did at 25.

Treatment Options and What to Expect

Once GHD is confirmed, the standard treatment is recombinant human growth hormone (rhGH), administered as daily subcutaneous injections. The starting dose is typically low, around 0.2 mg per day for men and 0.3 mg per day for women (women generally need slightly higher doses because estrogen attenuates GH signaling). The dose is then titrated upward based on IGF-1 levels, symptom response, and side effects.

AACE recommends targeting IGF-1 levels in the middle to upper portion of the age-adjusted reference range rather than the top. This reflects a balanced approach that aims for clinical benefit while minimizing the risk of side effects associated with supraphysiological GH exposure. The days of targeting the highest possible IGF-1 are giving way to a more measured strategy, especially as the data on the relationship between high IGF-1 and cancer risk continues to develop.

Treatment benefits typically develop over weeks to months. Improvements in body composition (less visceral fat, more lean mass) are usually the first noticeable changes, followed by improved energy, better exercise capacity, and enhanced mood. Bone density improvements take longer, often requiring 12 to 18 months of consistent therapy to become measurable on a DEXA scan.

Monitoring and Follow-Up

Ongoing monitoring is a cornerstone of responsible GH replacement therapy. AACE recommends regular assessment of IGF-1 levels to guide dose adjustments, along with metabolic monitoring including fasting glucose, HbA1c, and lipid panels. Bone density scans should be performed periodically, especially in patients who had low bone density at baseline. And any new symptoms, particularly changes in vision, headaches, or unexplained swelling, should be evaluated promptly.

Side effects of GH replacement at appropriate doses are generally mild and manageable. Fluid retention, joint stiffness, and carpal tunnel-like symptoms are the most common. These often resolve with dose reduction. The metabolic effects on blood sugar are usually modest at replacement doses but still warrant monitoring, particularly in patients with pre-existing insulin resistance or diabetes risk factors.

Practical Takeaways for Patients and Practitioners

If you suspect you might have GHD, the path forward starts with a conversation with an endocrinologist who has experience with pituitary disorders. A general practitioner may not think to test for it, especially if your symptoms are being attributed to depression, aging, or lifestyle factors. Bringing up the possibility yourself, particularly if you have any of the risk factors mentioned above, can be the catalyst that leads to proper diagnosis.

For practitioners, the AACE guidelines provide a clear framework for when to test, how to diagnose, and how to treat. The emphasis on proper stimulation testing rather than relying solely on IGF-1 levels is important because it prevents both underdiagnosis (missing GHD in someone with a normal IGF-1) and overdiagnosis (treating normal age-related decline as if it were pathological).

Insurance coverage for GH therapy in adults with confirmed GHD is available but often requires documentation of the stimulation test results, the clinical indication, and sometimes a trial period showing benefit. The out-of-pocket cost without insurance can be substantial, making proper diagnosis and documentation even more important for patients who need therapy but cannot easily afford it.

The overarching message from the AACE guide is that adult GHD is a legitimate, diagnosable, treatable condition that deserves the same clinical attention as other hormonal deficiencies. It should not be dismissed, but it also should not be self-diagnosed based on vague symptoms and treated with unregulated peptides purchased online. The diagnostic process exists for a reason, and it protects patients from both undertreatment and overtreatment.

Quality of Life and the Broader Impact of GHD Treatment

One aspect of adult GHD that deserves more attention is its impact on quality of life beyond the measurable biomarkers. Patients with untreated GHD consistently report lower quality of life scores on validated questionnaires compared to age-matched controls. The fatigue is not ordinary tiredness; it is a pervasive exhaustion that does not respond to rest. The psychological effects, including social isolation, reduced motivation, and a persistent sense of diminished capacity, can be profoundly disruptive to personal and professional life.

Treatment often produces improvements in these subjective domains that patients describe as transformative. The ability to exercise without days of recovery, improved sleep quality, better cognitive clarity, and restored social engagement are commonly reported within the first few months of appropriate GH replacement. These quality-of-life improvements, while harder to quantify than changes in body composition or bone density, are often the outcomes that matter most to patients.

The healthcare system does not always handle GHD well. Patients may see multiple providers before reaching an endocrinologist who considers GHD in the differential diagnosis. The stimulation testing required for diagnosis is not available in every clinic, and some providers are unfamiliar with the testing protocols or the nuances of interpretation. Patient advocacy, including bringing research-backed information to appointments and requesting referrals to pituitary specialists, can make the difference between years of misdiagnosis and timely, effective treatment.

Support communities, both online and through organizations like the Pituitary Society and the MAGIC Foundation, provide resources and peer connection that can be valuable for patients navigating the diagnostic and treatment process. Living with a rare-ish hormonal condition can feel isolating, and connecting with others who share the experience provides both practical guidance and emotional support that the medical system alone may not offer.